TY - JOUR
T1 - Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent
T2 - A patient-level pooled analysis of eight registry studies
AU - Grundeken, Maik J.
AU - Asgedom, Solomon
AU - Damman, Peter
AU - Lesiak, Maciej
AU - Norell, Michael S.
AU - Garcia, Eulogio
AU - Bethencourt, Armando
AU - Woudstra, Pier
AU - Koch, Karel T.
AU - Vis, Marije M.
AU - Henriques, Jose P.S.
AU - Onuma, Yoshinobu
AU - Foley, David P.
AU - Bartorelli, Antonio L.
AU - Stella, Pieter R.
AU - Tijssen, Jan G.P.
AU - De Winter, Robbert J.
AU - Wykrzykowska, Joanna J.
PY - 2013
Y1 - 2013
N2 - Aims: Smaller studies have previously shown promising results after Tryton Side Branch Stent™ (Tryton Medical, Durham, NC, USA) placement. However, these previous studies were limited by their small sample size and relatively short follow-up. We performed a patient-level pooled analysis to evaluate six-month and one-year clinical outcomes of more than 900 patients who were enrolled in eight registries with the Tryton stent. Methods and results: Data from eight Tryton registries, including 905 patients with 929 bifurcation lesions, were pooled on a patient level to form one dataset. The primary outcome was six-month target vessel failure (TVF), defined as the composite of cardiac death, any myocardial infarction, and clinically indicated target vessel revascularisation. Procedural success was defined as successful stent placement and no in-hospital major adverse cardiac events. Multivariable analysis was performed to determine independent predictors for one-year TVF. Follow-up data were available in 97%. Procedural success was 95% and TVF rate was 6.5% at six months and 8.5% at one year. Stent thrombosis occurred in 0.5% of patients. Left main coronary artery bifurcation lesion (HR 6.46) and main branch reference vessel diameter <3.0 mm (HR 2.62) were independent predictors for TVF. Conclusions: In the real world setting of registries including more than 900 patients, the use of the Tryton stent is associated with procedural and mid-term clinical results that compare very favourably with historical studies. The primary endpoint of TVF was primarily determined by reference vessel diameter of the main branch and left main bifurcation lesion location.
AB - Aims: Smaller studies have previously shown promising results after Tryton Side Branch Stent™ (Tryton Medical, Durham, NC, USA) placement. However, these previous studies were limited by their small sample size and relatively short follow-up. We performed a patient-level pooled analysis to evaluate six-month and one-year clinical outcomes of more than 900 patients who were enrolled in eight registries with the Tryton stent. Methods and results: Data from eight Tryton registries, including 905 patients with 929 bifurcation lesions, were pooled on a patient level to form one dataset. The primary outcome was six-month target vessel failure (TVF), defined as the composite of cardiac death, any myocardial infarction, and clinically indicated target vessel revascularisation. Procedural success was defined as successful stent placement and no in-hospital major adverse cardiac events. Multivariable analysis was performed to determine independent predictors for one-year TVF. Follow-up data were available in 97%. Procedural success was 95% and TVF rate was 6.5% at six months and 8.5% at one year. Stent thrombosis occurred in 0.5% of patients. Left main coronary artery bifurcation lesion (HR 6.46) and main branch reference vessel diameter <3.0 mm (HR 2.62) were independent predictors for TVF. Conclusions: In the real world setting of registries including more than 900 patients, the use of the Tryton stent is associated with procedural and mid-term clinical results that compare very favourably with historical studies. The primary endpoint of TVF was primarily determined by reference vessel diameter of the main branch and left main bifurcation lesion location.
KW - Coronary artery disease
KW - Coronary bifurcation lesion
KW - Dedicated bifurcation stent
KW - Tryton side branch stent
UR - http://www.scopus.com/inward/record.url?scp=84880013164&partnerID=8YFLogxK
U2 - 10.4244/EIJV9I2A34
DO - 10.4244/EIJV9I2A34
M3 - Article
C2 - 23360690
AN - SCOPUS:84880013164
SN - 1774-024X
VL - 9
SP - 195
EP - 203
JO - EuroIntervention
JF - EuroIntervention
IS - 2
ER -